



Technology: Insulin glargine is a long-acting recombinant human insulin analog that helps to control blood sugar levels in patients with diabetes.

Insulin Glargine Timeline



Insulin Glargine Challenged Claim Types in IPR and Litigation*



*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints. Joinder counted separately.

Spotlight On: Insulin Glargine

February 28, 2025

	<i>Sanofi v. Eli Lilly</i> 1:14-cv-00113 (D. Del.) Settled	<i>Sanofi v. Eli Lilly</i> 1:14-cv-00884 (D. Del.) Settled	<i>Sanofi v. Merck</i> 1:16-cv-00812 (D. Del.) Stipulated dismissal	<i>Sanofi v. Merck</i> 2:17-cv-05914 (D.N.J.) Stipulated dismissal	<i>Sanofi v. Mylan</i> 2:17-cv-09105 (D.N.J.) Claims not infringed, but invalid Appeal 21-1262 Dismissed as Moot	<i>Mylan v. Sanofi</i> IPR2017-01526 FWD (All instituted claims unpatentable); Appeal 19-1368 Affirmed, Rehearing denied; Sup. Ct. 19-1451 Cert Denied	<i>Mylan v. Sanofi</i> IPR2017-01528 FWD (All instituted claims unpatentable); Appeal 19-1369 Affirmed, Rehearing denied; Sup. Ct. 19-1451 Cert Denied	<i>Mylan v. Sanofi</i> IPR2018-01670 FWD (Instituted claim unpatentable) Appeal 20-1871 Pending <i>Pfizer v. Sanofi</i> IPR2019-00979 (Joinder denied) FWD (All instituted claims unpatentable); Appeal 20-2159 Affirmed	<i>Mylan v. Sanofi</i> IPR2018-01675 IPR2018-01676 <i>Pfizer v. Sanofi</i> IPR2019-00977 IPR2019-00978 Joined FWD (All instituted claims unpatentable); Appeals 20-2029 Dismissed as Moot, 20-2032 Affirmed	<i>Mylan v. Sanofi</i> IPR2018-01677 Terminated prior to institution decision; Refiled as IPR2019-00122, <i>Pfizer v. Sanofi</i> IPR2019-00982 Joined FWD (All instituted claims unpatentable); Appeal 20-2034 Dismissed as Moot	<i>Mylan v. Sanofi</i> IPR2018-01678 IPR2018-01679 <i>Pfizer v. Sanofi</i> IPR2019-00980 IPR2019-00981 Joined FWD (All instituted claims unpatentable); Appeals 20-2033, 20-2066 Affirmed
7,476,652	x	x	x	x	x	x					
7,713,930	x	x	x	x	x		x				
7,918,833		x	x		x						
8,512,297		x	x		x						
8,556,864	x	x	x		x						
8,603,044	x	x	x		x				x		
8,679,069	x	x	x		x			x			
8,992,486			x		x					x	x
9,011,391			x		x						
9,233,211			x		x						
9,408,979					x						
9,457,152			x								
9,486,587			x				<i>Mylan v. Sanofi</i> IPR2019-01658 Institution denied	<i>Mylan v. Sanofi</i> IPR2019-01657 FWD (All instituted claims unpatentable); Appeal 21-1981 Reversed	<i>Mylan v. Sanofi</i> IPR2018-01680 IPR2018-01682 <i>Pfizer v. Sanofi</i> IPR2019-01022 IPR2019-01023 Joined FWD (All instituted claims unpatentable); Appeals 20-2068 Affirmed, 20-2069 Dismissed as Moot	<i>Mylan v. Sanofi</i> IPR2018-01696 Institution denied	<i>Mylan v. Sanofi</i> IPR2018-01684 <i>Pfizer v. Sanofi</i> IPR2019-00987 Joined FWD (Some instituted claims unpatentable); Appeal 20-2071 Affirmed, 20-2139 & 20-2144 Withdrawn
9,526,844			x		x				x	x	
9,533,105			x		x						
9,561,331					x						
9,592,348			x								
9,604,008			x		x						x
9,604,009					x						
9,610,409					x						
9,623,189					x						
RE47,614							x	x			